Results 11 to 20 of about 251,433 (257)

Can angiogenesis inhibitor therapy cause changes in imaging features of hepatic hemangioma- Initial study. [PDF]

Front Oncol, 2023
BackgroundTo observe whether anti-angiogenesis therapy can induce changes in size and enhancement characteristics of hepatic hemangioma.Method133 patients with hepatic hemangioma lesions were analyzed and classified into a Bevacizumab group (n=65) and ...
Liu T, Pan W, Lai S, Luo J.
europepmc   +2 more sources

First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China. [PDF]

Cancer Med, 2023
Background Currently, survival benefit of immunotherapy in advanced non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) is controversial, though it generally indicates poor response and activity.
Yang G, Yang Y, Liu R, Li W, Xu H, Hao X, Li J, Zhang S, Xu F, Lei S, Wang Y.   +10 more
europepmc   +2 more sources

Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma. [PDF]

Front Oncol, 2023
BackgroundLiposarcomas (LPS) are mesenchymal malignancies with four principal subtypes presenting distinct molecular and clinical features. Pleomorphic liposarcoma (PLPS) is one of the rarest and most aggressive subtypes of LPS.
Zhang C, Liu W, Wang B, Zhu N, Guo X, Wang Z, Zhuang R, You Y, Zhang Y, Tong H, Lu W, Zhou Y.   +11 more
europepmc   +2 more sources

On-Target Side Effects of Targeted Therapeutics of Cancer

Pathology and Oncology Research, 2022
The concept of precision medicine is based on the identification of hallmarks of cancer to exploit them as drug targets. The basic idea was that in this way the therapeutic modalities will be more effective and the side effects will be less.
József Tímár, Andrea Uhlyarik
doaj   +1 more source

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation. [PDF]

Cancer Med, 2021
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are currently the primary treatment option for patients with EGFR‐mutant non‐small cell lung cancer (NSCLC).
Kodama H, Kenmotsu H, Kawabata T, Notsu A, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Takahashi T.   +15 more
europepmc   +2 more sources

The first Russian register of patients with neovascular age-related macular degeneration: a real-world clinical study

Российский офтальмологический журнал, 2023
Purpose: data analysis of Russia’s first register of neovascular age-related macular degeneration (nAMD) — a web-based system for clinical monitoring of nAMD patients designed to collect and accumulate the data on such patients, their demographic, social
V. V. Neroev, O. V. Zaytseva, V. A. Petrakovskaya, M. A. Trifonova, E. I. Ganeeva   +4 more
doaj   +1 more source

Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs

Diagnostics, 2023
Background: Body composition could help to better define the prognosis of cancers treated with anti-angiogenics. The aim of this study is to evaluate the prognostic value of 3D and 2D anthropometric parameters in patients given anti-angiogenic treatments.
Pierre Decazes, Samy Ammari, Antoine De Prévia, Léo Mottay, Littisha Lawrance, Younes Belkouchi, Baya Benatsou, Laurence Albiges, Corinne Balleyguier, Pierre Vera, Nathalie Lassau   +10 more
doaj   +1 more source

An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model

Scientific Reports, 2021
In order to identify more effective therapy for recalcitrant osteosarcoma, we evaluated the efficacy of an mTOR-VEGFR inhibitor combination on tumor growth in a unique osteosarcoma patient-derived orthotopic xenograft (PDOX) mouse model derived from the ...
Hiromichi Oshiro, Yasunori Tome, Kentaro Miyake, Takashi Higuchi, Norihiko Sugisawa, Fuminori Kanaya, Kotaro Nishida, Robert M. Hoffman   +7 more
doaj   +1 more source

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Frontiers in Pharmacology, 2023
Currently, for ovarian cancer, which has the highest mortality rate among all gynecological cancers, the standard treatment protocol is initial tumor cytoreductive surgery followed by platinum-based combination chemotherapy.
Xu Huang, Xu Huang, Xiao-Yu Li, Xiao-Yu Li, Wu-Lin Shan, Yao Chen, Qi Zhu, Bai-Rong Xia   +7 more
doaj   +1 more source

A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression

Frontiers in Pharmacology, 2020
Angiogenesis dysregulation contributes to inflammation, infections, immune disorders, and carcinogenesis. Bromodomain-containing protein 4 (BRD4) is an epigenetic reader that recognizes histone proteins and acts as a transcriptional regulator to trigger ...
Zijun Zhou, Xiaoming Li, Zhiqing Liu, Lixun Huang, Yuying Yao, Liuyou Li, Jian Chen, Rongxin Zhang, Rongxin Zhang, Jia Zhou, Lijing Wang, Lijing Wang, Qian-Qian Zhang, Qian-Qian Zhang   +13 more
doaj   +1 more source